Muscarinic M1 and M4 receptors (agonist)

Assets acting on this target.

Class
Muscarinic M1/M4 receptor agonist
Pathway
Activation of both M1 and M4 muscarinic receptor subtypes in the CNS; preclinical knockout studies indicate both subtypes contribute to antipsychotic-like activity across multiple psychosis models.

Muscarinic acetylcholine receptors are G protein-coupled receptors that mediate the actions of acetylcholine throughout the central and peripheral nervous systems. Five subtypes exist (M1–M5), each coupling to distinct intracellular signaling pathways and showing different tissue distributions. M1 and M4 are enriched in brain regions implicated in cognition, mood, and psychosis, including the striatum, hippocampus, and cortex. Preclinical genetic and pharmacological studies indicate that stimulating M1 and M4 can produce antipsychotic-like effects without directly blocking dopamine D2 receptors, the mechanism shared by essentially all approved antipsychotic medicines. This offers a potential route to treating psychosis through a different pathway, one that may address symptoms poorly responsive to dopamine-based drugs and could avoid some of the motor and metabolic effects associated with D2 blockade. Because muscarinic receptors are also densely expressed outside the brain, in the gut, bladder, cardiovascular system, and glands, broadly acting agonists risk causing peripheral cholinergic side effects. Pairing a brain-active M1/M4 agonist with an antagonist that does not cross the blood-brain barrier is a strategy intended to blunt those peripheral effects while preserving central activity, illustrating how selectivity and formulation choices can be used to widen a therapeutic window.

By indication

Related mechanisms

Muscarinic M1 and M4 receptors (agonist) drugs compared

2 drugs, stage by indication
2 drugs acting on Muscarinic M1 and M4 receptors (agonist): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Betovumeline/fesoterodine (ML-007C-MA)MapLight Therapeuticssmall moleculePhase 2Phase 2 in Alzheimer's Disease; Phase 2 in Alzheimer's Disease Psychosis; Phase 2 in Schizophrenia
NBI-1117570Neurocrine Biosciencessmall moleculePhase 2Phase 2 in Schizophrenia

← all mechanisms